NxStage Medical to Medicare: Really?

Tue, 08/07/2012 - 3:25pm
Mass Device

NxStage Medical expresses disappointment and disbelief that the Centers for Medicare & Medicaid failed to update rules for home hemodialysis.

NxStage Medical logo

NxStage Medical (NSDQ:NXTM) regained some points on Wall Street after issuing public statement challenging the Centers for Medicare & Medicaid on its uninspiring policies for home hemodialysis.

NxStage North America president Joe Turk took a firm stand against what he perceives as a lack of support for at-home hemodialysis treatment for Medicare patients with kidney failure, despite a growing consensus among private insurers that the procedure is "medically necessary" for some patients.

In a letter glibly titled "Really?", Turk outlined his disappointment in the policy as proposed, offered a few quick fixes and urged stakeholders to submit suggestions on the rule during the open comment period - before the proposal becomes policy.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.